pamufetinib

Pamufetinib (TAS-115) is an orally administered, ATP-competitive small molecule inhibitor that targets multiple receptor tyrosine kinases, including the hepatocyte growth factor receptor (c-Met), vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and FMS-like tyrosine kinase 3 (FMS). It inhibits these kinases by blocking their autophosphorylation in an ATP-competitive manner. Pamufetinib was initially developed as an anticancer agent and has demonstrated antitumor activity in preclinical models, particularly against solid tumors and osteosarcoma. Additionally, it has shown potential antifibrotic effects by inhibiting fibroblast proliferation and migration through its action on PDGFR and VEGFR pathways. The drug is being investigated for use in various indications including osteosarcoma, idiopathic pulmonary fibrosis (IPF), interstitial lung diseases, prostate cancer, and other solid tumors[1][2][3][4][5][6][8].

Other names

pamufetinibTAS-115TAS115TAS 115